This study will assess two treatment options for pulmonary embolism (a clot in the blood vessels in your lung). One treatment using ultrasound guided thrombolysis and anticoagulation (procedures that break up blood clots). Compared with treatment with anticoagulation alone. Mortality (death), cardiorespiratory decompensation (reduced heart function) or collapse within 7 days will be assessed and compared.
This study is a multicentre, open label (participants know their treatment) trial. Patients with FIGO stage III epithelial ovarian cancer, eligible for surgery to reduce the amount of cancer in their body, will be included. They will be randomised to receive surgery with or without hyperthermic intraperitoneal chemotherapy (where a dose of heated chemotherapy is provided after surgery).
This study will evaluate the effectiveness, safety and tolerability of a drug, remibrutinib, as a treatment for patients with relapsing multiple sclerosis.
This study will evaluate the effectiveness and dose-response of a drug, atacicept, in reducing high levels of protein in urine (proteinuria). Atacicept will be compared to placebo (a sugar pill with no active drug) in participants with IgAN (immunoglobulin A nephropathy) and persistent proteinuria.
